Menu

Investors

Results centre Shareholder information

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

2018 Interim Results

Results centre

Net assets

£1,394.0m

Fully diluted NAV per share

£2.08

NAV total return

32.5%

Life science portfolio return

62.6%

Capital pool available to invest in life science

£448.3m

% of net assets invested in life science

68.0%

HY2018 Business Catalysts

  • Continued positive sales progress in Blue Earth
  • Data read-outs in seven ongoing clinical trials; two new clinical trials expected to commence
  • New financings, companies and programme initiations

Regulatory news

View all
Autolus announces closing of public offering
16.04.2019
View
Autolus announces pricing of public offering
11.04.2019
View
Creation of leading retinal gene therapy platform
11.04.2019
View
Autolus announces launch of proposed offering
09.04.2019
View

Who we are

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Our opportunity

Today, there is rising global demand for healthcare, fuelled by ageing global populations, increased knowledge and awareness amongst the patient community, and the growing prevalence of chronic diseases.